Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 2426 - 2450 of 15136 in total
DaxibotulinumtoxinA is an acetylcholine release inhibitor and neuromuscular blocking agent. It is a botulinum toxin without accessory proteins purified from the bacterium Clostridium botulinum type A, the gram-positive anaerobic bacterium primarily present in soil. C. botulinum is known to produce toxins that can cause botulism in humans.[A261075, L47860] DaxibotulinumtoxinA was...
Approved
Matched Description: … DaxibotulinumtoxinA is an acetylcholine release inhibitor and neuromuscular blocking agent. …
Leniolisib is a potent and selective inhibitor of phosphoinositide 3-kinase δ (PI3Kδ). The FDA approved leniolisib on March 24, 2023, making it the first treatment for activated phosphoinositide 3-kinase delta syndrome (APDS). APDS is a primary immunodeficiency caused by mutations in genes encoding the PI3Kδ, thereby increasing the activity of...
Approved
Investigational
Matched Description: … Leniolisib is a potent and selective inhibitor of phosphoinositide 3-kinase δ (PI3Kδ). ... in genes encoding the PI3Kδ, thereby increasing the activity of PI3Kδ, causing immune dysfunction, and
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Tolterodine is an antimuscarinic drug that is used to treat urinary incontinence. Tolterodine acts on M2 and M3 subtypes of muscarinic receptors.
Approved
Investigational
Matched Description: … Tolterodine acts on M2 and M3 subtypes of muscarinic receptors. …
Matched Categories: … Genito Urinary System and Sex Hormones ... Drugs for Urinary Frequency and Incontinence …
Deutetrabenazine is a novel, highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the management of chorea associated with Huntington’s disease. It is a hexahydro-dimethoxybenzoquinolizine derivative and a deuterated DB04844 . The presence of deuterium in deutetrabenazine increases the half-lives of the active metabolite and prolongs their pharmacological activity...
Approved
Investigational
Matched Description: … It is a hexahydro-dimethoxybenzoquinolizine derivative and a deuterated [DB04844] [A32046]. ... This allows less frequent dosing and a lower daily dose with improvement in tolerability [A32043]. ... It was approved by FDA in April 2017 and is marketed under the trade name Austedo as oral tablets. …
Matched Categories: … Tetrabenazine and isomer …
Crofelemer, previously known as the investigational drug SP-303, is a novel proanthocyanidin purified from the bark latex of the Amazonian Croton tree Croton lechleri. It is marketed under the brand name Fulyzaq and indicated for the symptomatic treatment of non-infectious diarrhea in adult patients with HIV/AIDS who are taking antiretroviral...
Approved
Matched Description: … It is marketed under the brand name Fulyzaq and indicated for the symptomatic treatment of non-infectious …
Matched Categories: … Alimentary Tract and Metabolism …
Drug-resistant bacteria, such as methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and penicillin-resistant Streptococcus penumoniae, represent a massive public health threat.[A199086, A199131] Tedizolid is a member of the oxazolidinone class of antibiotics, which includes the previously approved linezolid and is generally effective against multidrug-resistant Gram-positive bacteria. Tedizolid is indicated for the...
Approved
Investigational
Matched Description: … ) and is generally more effective and more tolerable than [linezolid]. ... such as methicillin-resistant _Staphylococcus aureus_, vancomycin-resistant _Enterococcus faecium_, and ... member of the oxazolidinone class of antibiotics, which includes the previously approved [linezolid] and
2,2'-Dibenzothiazyl disulfide is an accelerator used in the processing process for natural and synthetic rubber and plastic regeneration. It is also a known allergen and dermatological sensitizer. Sensitivity to 2,2'-Dibenzothiazyl disulfide may be identified with a clinical patch test.
Approved
Experimental
Matched Description: … rubber and plastic regeneration. ... It is also a known allergen and dermatological sensitizer. ... 2,2'-Dibenzothiazyl disulfide is an accelerator used in the processing process for natural and synthetic …
Duloxetine is a dual serotonin and norepinephrine reuptake inhibitor.[label] It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686. Duloxetine first received approval from the FDA in August, 2004 as Cymbalta for the treatment of Major Depressive Disorder. It has since received approval for a...
Approved
Matched Description: … [label] It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686. ... Duloxetine is a dual serotonin and norepinephrine reuptake inhibitor. ... Duloxetine continues to be investigated for the treatment of pain in cancer, surgery, and more. …
Matched Categories: … Serotonin and Noradrenaline Reuptake Inhibitors …
Riociguat is a soluble guanylate cyclase (sGC) agonist approved in the USA, Europe and several other regions for patients with group I PAH (pulmonary arterial hypertension) in WHO FC II or III; and for the treatment of patients with inoperable CTEPH (chronic thromboembolic pulmonary hypertension), or persistent/recurrent PH (pulmonary hypertension)...
Approved
Matched Description: … Riociguat is a soluble guanylate cyclase (sGC) agonist approved in the USA, Europe and several other ... regions for patients with group I PAH (pulmonary arterial hypertension) in WHO FC II or III; and for …
A muscarinic antagonist that has effects in both the central and peripheral nervous systems. It has been used in the treatment of arteriosclerotic, idiopathic, and postencephalitic parkinsonism. It has also been used to alleviate extrapyramidal symptoms induced by phenothiazine derivatives and reserpine.
Approved
Investigational
Matched Description: … A muscarinic antagonist that has effects in both the central and peripheral nervous systems. ... It has been used in the treatment of arteriosclerotic, idiopathic, and postencephalitic parkinsonism. ... It has also been used to alleviate extrapyramidal symptoms induced by phenothiazine derivatives and reserpine …
Levobupivacaine is an amino-amide local anaesthetic drug belonging to the family of n-alkylsubstituted pipecoloxylidide. It is the S-enantiomer of bupivacaine. Levobupivacaine hydrochloride is commonly marketed by AstraZeneca under the trade name Chirocaine. In particular, the specific levobupivacaine enantiomer is a worthwhile pursuit because it demonstrates less vasodilation and possesses a...
Approved
Investigational
Matched Description: … intrathecal anaesthesia in adults; and infiltration analgesia in children. ... specific levobupivacaine enantiomer is a worthwhile pursuit because it demonstrates less vasodilation and ... predominantly associated with inappropriate administration methods that may cause systemic exposure and
Plerixafor is a small-molecule inhibitor of C-X-C chemokine receptor type 4 (CXCR4) that acts as a hematopoietic stem cell mobilizer.[A7117,L45678] It is used to stimulate the release of stem cells from the bone marrow into the blood in patients with non-Hodgkin's lymphoma (NHL) and multiple myeloma to stimulate their immune...
Approved
Investigational
Matched Description: … [A7115] Plerixafor has orphan drug status in the United States and European Union and was approved ... Since CXCR4 and SDF-1α are involved in the trafficking and homing of CD34+ cells to the marrow compartment ... by the US Food and Drug Administration on December 15, 2008. …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Pegulicianine is an optical imaging agent indicated for fluorescence imaging in patients with breast cancer. It is used following surgical resection of the primary tumor to detect areas of remaining cancer. Pegulicianine itself is a prodrug comprising three main fragments, one of which contains a fluorescence quencher that keeps the...
Approved
Matched Description: … [L50537,L50547] It received Fast Track and priority review for this indication.[L50547] …
HIV/AIDS remains an area of concern despite the introduction of numerous successful therapies, mainly due to the emergence of multidrug resistance and patient difficulty in adhering to treatment regimens.[A244170, A244175] Lenacapavir is a first-in-class capsid inhibitor that demonstrates picomolar HIV-1 inhibition as a monotherapy in vitro, little to no cross-resistance...
Approved
Investigational
Matched Description: … introduction of numerous successful therapies, mainly due to the emergence of multidrug resistance and ... inhibition as a monotherapy _in vitro_, little to no cross-resistance with existing antiretroviral agents, and
Hemin (trade name Panhematin) is an iron-containing porphyrin. More specifically, it is protoporphyrin IX containing a ferric iron ion (heme B) with a chloride ligand.
Approved
Investigational
Matched Categories: … Blood and Blood Forming Organs …
Clothiapine has been approved in European countries and is an atypical antipsychotic, shown to be useful in some treatment-resistant patients.
Approved
Matched Description: … Clothiapine has been approved in European countries and is an atypical antipsychotic, shown to be useful …
Matched Categories: … Diazepines, Oxazepines, Thiazepines and Oxepines …
Zinc dibutyldithiocarbamate is a dermatological sensitizer and allergen. Sensitivity to zinc dibutyldithiocarbamate may be identified with a clinical patch test.
Approved
Experimental
Matched Description: … Zinc dibutyldithiocarbamate is a dermatological sensitizer and allergen. …
Matched Categories: … Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use …
A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike physostigmine, does not cross the blood-brain barrier.
Approved
Vet approved
Matched Description: … relaxants such as gallamine and tubocurarine. ... A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle …
Matched Categories: … Antiglaucoma Preparations and Miotics …
P-chlorophenol is a white crystals with a strong phenol odor. Slightly soluble to soluble in water, depending on the isomer, and denser than water. Noncombustible.
Approved
Matched Description: … Slightly soluble to soluble in water, depending on the isomer, and denser than water. …
Ticlopidine is an effective inhibitor of platelet aggregation. It is a prodrug that is metabolised to an active form, which blocks the ADP receptor that is involved in GPIIb/IIIa receptor activation leading to platelet aggregation. Ticlopidine is marketed under the brand name Ticlid and is indicated for patients who cannot...
Approved
Matched Description: … Ticlopidine is marketed under the brand name Ticlid and is indicated for patients who cannot take aspirin ... includes a black-box warning of neutropenia, aplastic anemia, thrombotic thrombocytopenia purpura, and ... agranulocytosis, so it is necessary to monitor patients' WBC and platelets when they are taking ticlopidine …
Matched Categories: … Blood and Blood Forming Organs ... Metabolic Side Effects of Drugs and Substances …
A muscarinic antagonist that crosses the blood-brain barrier and is used in the treatment of drug-induced extrapyramidal disorders and in parkinsonism.
Approved
Matched Description: … extrapyramidal disorders and in parkinsonism. ... A muscarinic antagonist that crosses the blood-brain barrier and is used in the treatment of drug-induced …
A radionuclide imaging agent used primarily in scintigraphy or tomography of the heart to evaluate the extent of the necrotic myocardial process. It has also been used in noninvasive tests for the distribution of organ involvement in different types of amyloidosis and for the evaluation of muscle necrosis in the...
Approved
Matched Description: … used in noninvasive tests for the distribution of organ involvement in different types of amyloidosis and
Matched Categories: … Indicators and Reagents …
Sotorasib, also known as AMG-510, is an acrylamide-derived KRAS inhibitor developed by Amgen.[A187547,A187556] It is indicated in the treatment of adult patients with KRAS G12C mutant non-small cell lung cancer. This mutation makes up >50% of all KRAS mutations. Mutant KRAS discovered in 1982 but was not considered a druggable...
Approved
Investigational
Matched Description: … [A187547] The drug [MRTX849] is also currently being developed and has the same target. …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Displaying drugs 2426 - 2450 of 15136 in total